Of the remaining 11 centers, only one center had a significantly higher rate (by Chi-square test) of TDP-43 assessment in participants diagnosed with FTLD (N = 30, 97% assessed for TDP-43) compared to participants with AD (N = 143, 68% assessed for TDP-43, P = 0.001). This evidence concerns the gene TARDBP and Alzheimer disease.